<DOC>
	<DOCNO>NCT02432027</DOCNO>
	<brief_summary>Evaluate effect topical C-82 psoriasis plaque test .</brief_summary>
	<brief_title>Trial Evaluate Topical C-82 Psoriasis Plaque Test</brief_title>
	<detailed_description>The primary objective trial evaluate antipsoriatic efficacy C-82 topical gel compare vehicle measurement thickness Echo Lucent Band ( ELB ) psoriatic infiltrate use 20 MHz sonography . To gain additional information possible efficacy change test field compare untreated plaque clinically assess visual scoring .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>mild moderate chronic stable plaque type psoriasis plaque thickness least 200 Âµm lesion ( ) trunk extremity ( exclude palms/soles ) skin must without disease finding skin disease psoriasis guttata , psoriasis punctata , psoriasis erythrodermatica , psoriasis arthropathica pustular psoriasis treatment locally act medication ( include antipsoriatics like vitamin D analogue , dithranol ) within 2 week precede trial treatment systemic medication ( include antipsoriatics like corticosteroid , cytostatics retinoids ) medication know provoke aggravate psoriasis ( e.g . betablocker , antimalarial drug , lithium ) phototherapy/PUVA within 4 week precede trial treatment biologics within 3 month precede trial know allergic reaction , irritation sensitivity active ingredient component investigational product ( e.g . Carbomere 940 , propylene glycol ) drug alcohol abuse symptom clinically significant illness within 4 precede trial participation another clinical trial within 4 week clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>